Effectiveness of sotalol treatment in symptomatic Brugada syndrome

Kathryn A. Glatter, Qing Wang, Mark Keating, Shenghan Chen, Nipavan Chiamvimonvat, Melvin M. Scheinman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.

Original languageEnglish (US)
Pages (from-to)1320-1322
Number of pages3
JournalAmerican Journal of Cardiology
Volume93
Issue number10
DOIs
StatePublished - May 15 2004

Fingerprint

Brugada Syndrome
Sotalol
Sodium Channels
Genetic Testing
Drug Therapy
Mutation
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effectiveness of sotalol treatment in symptomatic Brugada syndrome. / Glatter, Kathryn A.; Wang, Qing; Keating, Mark; Chen, Shenghan; Chiamvimonvat, Nipavan; Scheinman, Melvin M.

In: American Journal of Cardiology, Vol. 93, No. 10, 15.05.2004, p. 1320-1322.

Research output: Contribution to journalArticle

Glatter, Kathryn A. ; Wang, Qing ; Keating, Mark ; Chen, Shenghan ; Chiamvimonvat, Nipavan ; Scheinman, Melvin M. / Effectiveness of sotalol treatment in symptomatic Brugada syndrome. In: American Journal of Cardiology. 2004 ; Vol. 93, No. 10. pp. 1320-1322.
@article{ec2770add87a42a2a10939348315681c,
title = "Effectiveness of sotalol treatment in symptomatic Brugada syndrome",
abstract = "We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.",
author = "Glatter, {Kathryn A.} and Qing Wang and Mark Keating and Shenghan Chen and Nipavan Chiamvimonvat and Scheinman, {Melvin M.}",
year = "2004",
month = "5",
day = "15",
doi = "10.1016/j.amjcard.2004.02.023",
language = "English (US)",
volume = "93",
pages = "1320--1322",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Effectiveness of sotalol treatment in symptomatic Brugada syndrome

AU - Glatter, Kathryn A.

AU - Wang, Qing

AU - Keating, Mark

AU - Chen, Shenghan

AU - Chiamvimonvat, Nipavan

AU - Scheinman, Melvin M.

PY - 2004/5/15

Y1 - 2004/5/15

N2 - We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.

AB - We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.

UR - http://www.scopus.com/inward/record.url?scp=2342458202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342458202&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.02.023

DO - 10.1016/j.amjcard.2004.02.023

M3 - Article

C2 - 15135718

AN - SCOPUS:2342458202

VL - 93

SP - 1320

EP - 1322

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -